Wire · opportunities
FDA Expands Sevabertinib Indication for Nonsquamous Non-Small Cell Lung Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 September 2026 · Fusion42 review
The FDA granted accelerated approval to sevabertinib for adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with HER2 activating mutations, expanding its use to previously untreated patients. The decision was based on strong clinical trial results and included several safety warnings.
This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it.
◆ ◆ The Wire takeaway
You can now access a new first-line treatment option for NSCLC patients with HER2 mutations, opening a larger market segment. Prepare to update your clinical partnerships and awareness campaigns to capture this expanded indication.
◆ Coverage
7 sources · 9 Sep 2026
◆ Topics